Table 2.
Association between anticipatory nausea (AN) and patient characteristics and several medical factors
| AN (+) (n = 22) | AN (−) (n = 192) | P‐value | ||
|---|---|---|---|---|
| n (%) | ||||
| Age (years) | <50 | 7 (15) | 39 (85) | 0.20 |
| ≥50 | 15 (9) | 153 (91) | ||
| Sex | Female | 14 (11) | 116 (89) | 0.76 |
| Male | 8 (10) | 76 (90) | ||
| Cancer site | Breast | 7 (10) | 65 (90) | 0.25 |
| Colorectal | 7 (13) | 48 (87) | ||
| Lung | 0 (0) | 19 (100) | ||
| Lymphoma | 2 (13) | 14 (88) | ||
| Stomach | 2 (14) | 12 (86) | ||
| Others | 4 (11) | 34 (89) | ||
| Regimen | FOLFOX† | 3 (12) | 22 (88) | 0.19 |
| FEC100‡ | 5 (26) | 14 (74) | ||
| Paclitaxel | 1 (6) | 15 (94) | ||
| FOLFIRI§ | 2 (13) | 13 (87) | ||
| Gemcitabine | 2 (18) | 9 (82) | ||
| Trastuzumab | 0 (0) | 12 (100) | ||
| Others | 9 (8) | 107 (92) | ||
| Emetogenic level | Minimal or low risk | 4 (4) | 89 (96) | 0.01 |
| Moderate or high risk | 18 (14) | 103 (86) | ||
| Chemotherapy | Curative intent | 10 (12) | 72 (88) | 0.47 |
| Palliative intent | 12 (9) | 120 (91) | ||
| Performance status¶ | 0 | 16 (9) | 153 (91) | 0.43 |
| 1–3 | 6 (13) | 39 (87) | ||
†FOLFOX regimen contains fluorouracil and oxaliplatin. ‡FEC100 regimen contains 5‐fluorouracil, epirubicin, and cyclophosphamide. §FOLFIRI regimen contains fluorouracil and irinotecan. ¶Using the European Organization for the Research and Treatment of Cancer QLQ‐C30 questionnaire covering functional and symptom‐related aspects of quality of life in cancer patients.